Interestingly, the same study also suggested that breast cancer cell lines from the more aggressive triple-negative breast cancer (TNBC) and human epidermal growth factor receptor 2-positive (HER2+) subtypes exhibit a higher expression of WBP2 relative to those from the less aggressive oestrogen receptor-positive (ER+) subtype [62]. This evidence concerns the gene WBP2 and breast cancer.